Cerebrospinal fluid biomarkers in primary headache disorders

Headache

Volumn 46, Issue 7, 2006, Pages 1075-1087

  Harrington, Michael G ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

Biomarker identification; Cerebrospinal fluid biomarkers; Primary headache disorders

Indexed keywords

BIOLOGICAL MARKER; NEUROPEPTIDE; NEUROTRANSMITTER; PROTEIN;

BIOSYS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID EXAMINATION; CLUSTER HEADACHE; DATA BASE; HEADACHE; HIGH THROUGHPUT SCREENING; HUMAN; ISI; MEASUREMENT; MEDLINE; MIGRAINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCIFINDER; TENSION HEADACHE; TRIGEMINUS NEURALGIA;

BIOLOGICAL MARKERS; HEADACHE DISORDERS; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 33745612962     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00501.x     Document Type: Review

References (75)

1. Moskowitz MA, Bolay H, Dalkara T. Deciphering migraine mechanisms: Clues from familial hemiplegic migraine genotypes. Ann Neurol. 2004;55:276-280.
2. Quincke H. Zur pathologie der meningen. Deutsch Ztschr f Nervenh. 1910;40:78-130.
3. Quincke H. Uber meningitis serosa und verwandte zustande. Deutsch Ztschr f Nervenh. 1897;9:149-168.
4. Fumal A, Vandenheede M, Coppola G, et al. The syndrome of transient headache with neurological deficits and CSF lymphocytosis (HaNDL): Electrophysiological findings suggesting a migrainous pathophysiology. Cephalalgia. 2005;25:754-758.
5. Simonnet G, Taquet H, Floras P, et al. Simultaneous determination of radio-immunoassayable methionine-enkephalin and radioreceptor-active opiate peptides in CSF of chronic pain suffering and non suffering patients. Neuropeptides. 1986;7:229-240.
6. Kennedy JSGH, Schmidt DE, Johnson BW, et al. Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. Life Sci. 2002;71:1703-1715.
7. von Knorring L, Almay BG, Johansson F, Terenius L, Wahlstrom A. Circannual variation in concentrations of endorphins in cerebrospinal fluid. Pain. 1982;12:265-272.
8. Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology. 2004;63:427-435.
9. Elwan O, Abdella M, el Bayad AB, Hamdy S. Hormonal changes in headache patients. J Neurol Sci. 1991;106:75-81.
10. Von Storch TJC, Merritt HH. The cerebrospinal fluid during and between attacks of migraine headaches. Am J Med Sci. 1935;190:226-231.
11. Nappi G, Facchinetti F, Martignoni E, Petraglia F, Bono G, Genazzani AR. CSF beta-EP in headache and depression. Cephalalgia. 1985;5:99-101.
12. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 2004;24:735-739.
13. Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology. 2001;57:132-134.
14. Sarchielli P, Alberti A, Floridi A, Mazzotta G, Floridi A. Increased cerebrospinal fluid levels of nerve growth factor and brain-derived neurotrophic factor are not specific for chronic migraine. Cephalalgia. 2004;24:777.
15. Briseid K, Falkum A, Qvigstad EK, Stien R. Arginine esterase in cerebrospinal fluid and pro-arginine esterase in plasma from patients with migraine. Acta Neurol Scand. 1976;54:301-311.
16. Kunkle EC. Acetylcholine in the mechanism of headaches of migraine type. AMA Arch Neurol Psychiatry. 1959;81:135-141.
17. Barrie M, Jowett A. A pharmacological investigation of cerebro-spinal fluid from patients with migraine. Brain. 1967;90:785-794.
18. Castillo J, Martinez F, Suarez C, Naveiro J, Lema M, Noya M. Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia. 1996;16:56-61.
19. Kovacs K, Bors L, Tothfalusi L, et al. Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia. 1989;9:53-57.
20. Pool J, von Storch TJC, Lennox WG. Effect of ergotamine tartrate on pressure of cerebrospinal fluid and blood during migraine headache. Arch Intern Med. 1936;57:32-45.
21. Rothrock JF, Mar KR, Yaksh TL, Golbeck A, Moore AC. Cerebrospinal fluid analyses in migraine patients and controls. Cephalalgia. 1995;15:489-493.
22. Tunis M, Cardon P, Wolff H. Studies on headache: Cerebrospinal fluid pulse waves in migraine and in headache induced by amyl nitrite and histamine; action of ergotamine. AMA Arch Neurol Psychiatry. 1953;70:665.
23. Sicuteri F, Fanciullacci M, Geppetti P, Renzi D, Caleri D, Spillantini MG. Substance P mechanism in cluster headache: Evaluation in plasma and cerebrospinal fluid. Cephalalgia. 1985;5:143-149.
24. Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P. Glutamate and nitric oxide pathway in chronic daily headache: Evidence from cerebrospinal fluid. Cephalalgia. 2003;23:166-174.
25. Genazzani AR, Nappi G, Facchinetti F, et al. Progressive impairment of CSF beta-EP levels in migraine sufferers. Pain. 1984;18:127-133.
26. Harrington MG, Fonteh AN, Cowan RP, et al. Cerebrospinal fluid sodium increases in migraine. Headache. 2006.
27. Jain AC, Sethi NC, Babbar PK. A clinical electroencephalographic and trace element study with special reference to zinc, copper and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J Neurol. 1985;232:161.
28. Martinez F, Castillo J, Rodriguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993;13:89-93.
29. Bach FW, Langemark M, Ekman R, Rehfeld JF, Schifter S, Olesen J. Effect of sulpiride or paroxetine on cerebrospinal fluid neuropeptide concentrations in patients with chronic tension-type headache. Neuropeptides. 1994;27:129-136.
30. Komatsumoto S, Nara M. Lower level of endothelin-1 in migraine with aura. Rinsho Shinkeigaku. 1995;35:1250-1252.
31. Sarchielli P, Pini L, Rossi C, Baldi A, Floridi A, Calabresi P. Endocannabinoid levels in chronic migraine: Cerebrospinal fluid findings suggest a failure of this system. Cephalalgia. 2005;25:884.
32. Hardebo JE, Ekman R, Eriksson M. Low CSF metenkephalin levels in cluster headache are elevated by acupuncture. Headache. 1989;29:494-497.
33. Kostulas V, Eeg-Olofsson O, Olsson T, Link H. Demonstration in children of oligoclonal IgG bands in unconcentrated CSF using agarose isoelectric focusing and immunolabeling. Pediatr Neurol. 1986;2:286-289.
34. Bell RD, Rosenberg RN, Ting R, Mukherjee A, Stone MJ, Willerson JT. Creatine kinase BB isoenzyme levels by radioimmunoassay in patients with neurological disease. Ann Neurol. 1978;3:52-59.
35. Valenzuela RF, Donoso MV, Mellado PA, Huidobro-Toro JP. Migraine, but not subarachnoid hemorrhage, is associated with differentially increased NPY-like immunoreactivity in the CSF. J Neurol Sci. 2000;173:140-146.
36. Chapman LF, Wolff HG. Property of cerebrospinal fluid associated with disturbed metabolism of central nervous system. Science. 1958;128:1208-1209.
37. Chapman LF, Wolff HG. Studies of proteolytic enzymes in cerebrospinal fluid: Capacity of incubated mixtures of cerebrospinal fluid and plasma proteins to form vasodilator substances that contract the isolated rat uterus. AMA Arch Intern Med. 1959;103:86-94.
38. Fanciullacci M, Alessandri M, Nicolodi M, Michelacci S, Sicuteri F. Possible long-lasting inhibition of converting enzyme by enalapril in human cerebrospinal fluid. Clin Sci (Lond). 1993;84:313-317.
39. Kangasniemi P, Riekkinen P, Rinne UK. Kallikrein-like esterase and peptidase activities in CSF during migraine attacks and free intervals. Headache. 1972;12:66-68.
40. Kangasniemi P, Riekkinen P, Penttinen R, Ivaska K, Rinne UK. Enzyme changes in the cerebrospinal fluid and serum and their correlation to the breakdown of bradykinin during different stages of headache attacks of migraine patients. Headache. 1974;14:139-148.
41. Skinhoj E. Hemodynamic studies within the brain during migraine. Arch Neurol. 1973;29:95-98.
42. Castillo J, Martinez F, Corredera E, Lema M, Noya M. Migraine and histamine: Determining histidine in plasma and cerebrospinal fluid during migraine attacks. Rev Neurol. 1995;23:749-751.
43. Martelletti P, Romiti A, Gallo MF, Perrotta RA, Giacovazzo M. New contributions on extinction tests of essential headache. II. The test with indoprofen. Boll Soc Ital Biol Sper. 1983;59:1134-1138.
44. Sarchielli P, Rossi C, Coppola F, Floridi A, Floridi A, Calabresi P. Nociceptin and PGE2 levels in cerebrospinal fluid of chronic migraine and fibromyalgia patients. Cephalalgia. 2005;25:884.
45. Sarchielli P, Alberti A, Vaianella L, Floridi A, Mazzotta G, Floridi A. Levels of endogenous cannabinoids in the cerebrospinal fluid of chronic migraine patients. Cephalalgia. 2004;24:777.
46. Welch KM, Chabi E, Nell JH, et al. Biochemical comparison of migraine and stroke. Headache. 1976;16:160-167.
47. Martinez F, Castillo J, Leira R, Prieto JM, Lema M, Noya M. Taurine levels in plasma and cerebrospinal fluid in migraine patients. Headache. 1993;33:324-327.
48. Welch KM, Chabi E, Bartosh K, Achar VS, Meyer JS. Cerebrospinal fluid gamma aminobutyric acid levels in migraine. Br Med J. 1975;3:516-517.
49. Strittmatter M, Grauer M, Isenberg E, et al. Cerebrospinal fluid neuropeptides and monoaminergic transmitters in patients with trigeminal neuralgia. Headache. 1997;37:211-216.
50. Anselmi B, Baldi E, Casacci F, Salmon S. Endogenous opioids in cerebrospinal fluid and blood in idiopathic headache sufferers. Headache. 1980;20:294-299.
51. Salmon S, Bonciani M, Fanciullacci M, Marianelli L, Michelacci S, Sicuteri F. A putative 5-HT central feedback in migraine and cluster headache attacks. Adv Neurol. 1982;33:265-274.
52. Poloni M, Nappi G, Arrigo A, Savoldi F. Cerebrospinal fluid 5-hydroxyindoleacetic acid level in migrainous patients during spontaneous attacks, during headache-free periods and following treatment with L-tryptophan. Experientia. 1974;30:640-641.
53. Kangasniemi P, Sonninen V, Rinne UK. Excretion of free and conjugated 5-HIAA and VMA in urine and concentration of 5-HIAA and HVA in CSF during migraine attacks and free intervals. Headache. 1972;12:62-65.
54. Hyypp MT, Kangasniemi P. Variation of plasma free tryptophan and CSF 5-HIAA during migraine. Headache. 1977;17:25-27.
55. Zukerman S, Minatti-Hannuch SN, da Graca M, Mazzacoratti N, dos Reis Filho JB, Cavalheiro EA. Cerebrospinal fluid neurotransmitter amino acids in migraine. Cephalalgia. 1993;13:93.
56. Peres MF, Vieira DSS, Zukerman E, Soares CAS, Alonso EO, Faulhaber MH. Cerebrospinal fluid glutamate levels are decreased in chronic migraine patients using triptans. Cephalalgia. 2005;25:886.
57. Vecsei L, Widerlov E, Ekman R, et al. Suboccipital cerebrospinal fluid and plasma concentrations of somatostatin, neuropeptide Y and beta-endorphin in patients with common migraine. Neuropeptides. 1992;22:111-116.
58. Bach FW, Langemark M, Secher NH, Olesen J. Plasma and cerebrospinal fluid beta-endorphin in chronic tension-type headache. Pain. 1992;51:163-168.
59. Facchinetti F, Sances G, Martignoni E, Pagani I, Nappi G, Genazzani AR. Evidence of alpha-N-acetyl beta-endorphin in human cerebrospinal fluid. Brain Res. 1992;586:1-5.
60. Langemark M, Bach FW, Ekman R, Olesen J. Increased cerebrospinal fluid Met-enkephalin immunoreactivity in patients with chronic tension-type headache. Pain. 1995;63:103-107.
61. Nowak S, Ziolo H, Blaszczyk B. Fibrin fibrinogen degradation products in the cerebrospinal fluid of neurological patients. Neurol Neurochir Pol. 1984;18:541-545.
62. Shimomura T, Araga S, Kowa H, Takahashi K. Immunoglobulin kappa/lambda ratios in migraine and tension-type headache. Jpn J Psychiatry Neurol. 1992;46:721-726.
63. Harrington MG, Stochaj W, Cowan R. Major changes in the molecular composition of cerebrospinal fluid during migraine. Cephalalgia. 2001;21:343.
64. Huhmer AF, Biringer RG, Amato H, Fonteh AN, Harrington MG. Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. Dis Markers. 2006;22:211-234.
65. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics. 2005;5:290-296.
66. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001;41:646-657.
67. Nyholt DR, Morley KI, Ferreira MA, et al. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet. 2005;77:500-512.
68. Biringer RG, Hao Z, Harrington M, Hühmer AFR. Combined top-down, middle-down and bottom-up analysis of Apo A1 and PTGDS isolated from human CSF using ETD-linear ion trap and FT-mass spectrometry. In: American Society for Mass Spectrometry Annual Meeting: 2005. San Antonio, TX, 2005.
69. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3:1154-1169.
70. Hühmer AF, Biringer RG, Harrington MG. Quantification of CSF proteins from migraineurs in the headache and non-headache states using 16O/18O labeling and orbitrap ion trap mass spectrometry. In: ABRF Annual Meeting: 2006. Long Beach, CA, 2006.
71. Harrington MG, Biringer RF, Huhmer AF.FAs: Cerebrospinal fluid protein composition. J Neurochem. 2005;94(suppl 2):17.
72. Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggins JN, Harrington MG. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis Markers. 2006;22:247-272.
73. Harrington MG, Dalleska N, Navarro E, et al. Elemental analysis of cerebrospinal fluid, blood plasma and urine from headache and non-headache cohorts. In: American Headache Society Annual meeting 2002. Seattle, 2002.
74. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids. 2006 (in press).
75. Fonteh AN, Harrington RJ, Harrington MG. Quantification of free amino acids and dipeptides using isotope dilution liquid chromatography and electrospray ionization tandem mass spectrometry. Amino Acids. 2006 (in press).